PARI Pharma News

News

Stay up to date with the latest news from PARI and our pharmaceutical partners:

 


Tuesday, April 30, 2024
 

Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis


News published by Renovion Inc. concerning ARINA-1, a nebulized therapy administered via an optimized investigational eFlow® Technology nebulizer.

Read more

 


Tuesday, September 5, 2023
 

Insmed Announces Positive Topline Results From Phase 3 ARISE Study of ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with NTM Lung Disease Caused by MAC


News published by Insmed presenting data from ARIKAYCE® (amikacin liposome inhalation suspension), administered via the optimized eFlow® Technology nebulizer Lamira®.

Read more


Tuesday, June 27, 2023  

 

Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)


News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow® Technology nebulizer.

Read more


Tuesday, May 2, 2023
 

Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)


News published by Zambon concerning L-CsA-i, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Tuesday, April 18, 2023
 

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant


News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


 

Thursday, March 30, 2023  

 

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis


News published by Avalyn Pharma concerning AP02 (inhaled nintedanib), administered via an optimized eFlow® Technology nebulizer.

Read more


Thursday, March 30, 2023
 

Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in Lung Transplant Patients


News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Thursday, March 23, 2023
 

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile


News published by Avalyn Pharma concerning AP01 (inhaled pirfenidone), administered via an optimized eFlow® Technology nebulizer.

Read more


Wednesday, March 15, 2023
 

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia


News published by Recode Therapeutics concerning RCT1100, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Monday, January 09, 2023
 

Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound


News published by Spexis concerning murepavadin, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Wednesday, November 02, 2022
 

First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of NCFBE


News published by Renovion Inc. concerning ARINA-1, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Thursday, August 25, 2022
 

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)


News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow® Technology nebulizer.

Read more


Wednesday, August 03, 2022
 

Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program


News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Friday, June 17, 2022
 

Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic


News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow® Technology nebulizer.

Read more


Thursday, December 30, 2021
 

Polyphor closes merger with EnBiotix and is renamed Spexis


News published by Spexis concerning the closing of the merger of PARI’s partners Polyphor AG and EnBiotix Inc. and the change of name of the combined company to Spexis AG.

Read more


Tuesday, July 13, 2021
 

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial


News published by Savara Inc. concerning molgramostim (inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)), administered via an optimized eFlow® Technology nebulizer.

Read more


Friday, June 25, 2021
 

Dr. Stefan Seemann is appointed President of PARI Pharma GmbH


Dr. Stefan Seemann will replace Dr. Martin Knoch as President of PARI Pharma GmbH on July 1, 2021.

Read more


Tuesday, May 25, 2021
 

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial​


News published by Avalyn Pharma concerning AP01 (a formulation of pirfenidone optimized for delivery via inhalation), administered via an optimized eFlow® Technology nebulizer.

Read more


Thursday, May 20, 2021
 

Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference​​​​


News published by Insmed presenting data from, among others, ARIKAYCE® (amikacin liposome inhalation suspension), administered via an optimized eFlow® Technology nebulizer.​

Read more


Thursday, April 29, 2021
 

Key data on economic impact of Bronchiolitis Obliterans Syndrome (BOS) presented at ISHLT 2021


News published by Zambon, whose liposomal cyclosporine A for inhalation (L CsA i), which is in clinical development for the potential treatment of BOS, is administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Tuesday, March 23, 2021
 

LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)


PARI Pharma GmbH announces the authorization of the LAMIRA Nebulizer System for delivery of Insmed’s drug product ARIKAYCE®
(amikacin liposome inhalation suspension) in Japan.

Read more


Monday, March 1, 2021
 

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial


News published by Santhera Pharmaceuticals concerning Lonodelestat in cystic fibrosis, administered via an optimized eFlow® Technology nebulizer.

Read more


Thursday, January 7, 2021
 

Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease


News published by Insmed Incorporated concerning ARIKAYCE, administered using Lamira®, an optimized eFlow® Technology nebulizer.

Read more


Tuesday, December 22, 2020
 

Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin


News published by Polyphor concerning inhaled murepavadin, administered via an eFlow® Technology nebulizer.

Read more


Tuesday, November 24, 2020
 

Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled murepavadin


News published by Polyphor concerning the development of inhaled murepavadin, administered via an eFlow® Technology nebulizer.

Read more


Thursday, October 29, 2020
 

LAMIRA®, an eFlow® Technology nebulizer, is the only device to deliver Insmed’s ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union


PARI Pharma GmbH announces the issue of the CE declaration of conformity for its optimized eFlow Technology LAMIRA Nebuliser System.

Read more


Thursday, October 22, 2020
 

PARI's optimized Investigational eFlow® Technology nebulizer delivering well tolerated aerosols of AR-501 in Aridis´ Phase 1/2a clinical trial


PARI Pharma’s proprietary aerosol delivery platform, eFlow Technology, continues its long track record of success with Aridis Pharmaceuticals.

Read more


Friday, October 16, 2020
 

Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial


News published by Avalyn Pharma concerning AP01 (a formulation of pirfenidone optimized for delivery via inhalation), administered via an optimized eFlow® Technology nebulizer.

 


Tuesday, October 13, 2020
 

Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis


News published by Ionis Pharmaceuticals concerning IONIS-ENAC-2.5 Rx, administered via an optimized eFlow® Technology nebulizer.

Read more


Friday, July 24, 2020
 

Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options


News published by Insmed Incorporated concerning ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, administered with Lamira®, an optimized eFlow® Technology nebulizer.

Read more


Tuesday, July 7, 2020
 

New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease


News published by Insmed Incorporated concerning ARIKAYCE® (amikacin liposome inhalation suspension), administered with Lamira®, an optimized eFlow® Technology nebulizer.

Read more


Thursday, June 18, 2020
 

Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases


News published by Renovion, Inc. concerning their lead therapeutic candidate ARINA-1, administered via an optimized eFlow® Technology nebulizer.

Read more


Monday, June 1, 2020
 

Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference


News published by Biomarck Pharmaceuticals concerning its novel anti-MARCKS peptide BIO-11006 in non-small cell lung cancer (NSCLC), administered via an optimized eFlow® Technology nebulizer.

Read more


Tuesday, April 28, 2020
 

A new FDA Fast Track designation for Zambon

The designation is for L CsA i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a Zambon company


News published by Zambon concerning L-CsA-i, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Thursday, February 20, 2020
 

Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)


News published by Breath Therapeutics concerning L-CsA-i, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Monday, December 16, 2019
 

Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency


News published by Kamada Ltd. concerning inhaled AAT, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Tuesday, September 10, 2019
 

Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis


News published by Santhera Pharmaceuticals concerning POL6014 in cystic fibrosis, administered with an optimized investigational eFlow® Technology nebulizer.

Read more


Thursday, July 25, 2019
 

PARI Pharma spin-out Breath Therapeutics acquired by Zambon Pharma


News published by Zambon Pharma concerning the acquisition of biopharmaceutical company Breath Therapeutics

Read more

News published by Gimv concerning the sale of biopharmaceutical company Breath Therapeutics

Read more

News published by Sofinnova Partners concerning the sale of biopharmaceutical company Breath Therapeutics

Read more


Monday, May 20, 2019
 

New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease


News published by Insmed Incorporated concerning ARIKAYCE® (amikacin liposome inhalation suspension), administered with Lamira®, an optimized eFlow® Technology nebulizer.

Read more


Wednesday, May 1, 2019
 

Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019


News published by Sunovion Pharmaceuticals Inc. presenting data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019.

Read more


Tuesday, March 26, 2019
 

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.


News published by Breath Therapeutics concerning L-CsA-I, administered via an optimized investigational eFlow® Technology nebulizer.

Read more


Tuesday, October 2, 2018
 

PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).


ARIKAYCE® is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options

Read more


Thursday, December 7, 2017
 

MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow Technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)


LONHALA MAGNAIR Inhalation Solution is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S.

Read more

eFlow Technology nebulizers with digital therapy management: The PARI Connect eco-system

eFlow Technology nebulizers with digital therapy management

Learn how the PARI Connect system supports patients with carefully considered device usability and digital therapy management solutions.
 

Read more

Your innovative aerosol therapy – our drug-nebulizer expertise

YOUR innovative aerosol therapy – OUR drug-nebulizer expertise

Watch five short expert interviews containing all you need to know about our partnering approach for pharmaceutical companies.
 

Read more

Developing new drug-nebulizer combination products

Developing new drug-nebulizer combination products

Learn more about the critical success factors and opportunities for bringing a new vibrating membrane nebulizer as a drug-device combination product to the market.

Read more

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!
eFlow-partneringpari.com